Prostate medication, metabolism, and gut bacteria
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how prostate medication affects your metabolism and the helpful bacteria in your gut. It may help explain how these drugs work and how they affect your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing and able to give written consent to take part in the study.
- You can follow all study instructions and be available for the whole study.
- You have never had a fecal (stool) transplant.
- You have not had a stomach infection (gastroenteritis) in the last 3 months, or currently.
- You have not taken antibiotics in the last 3 months (except for prevention during a prostate biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
This trial collects tumor samples from men with prostate cancer to study the bacteria and other microbes inside the tumor. It aims to learn how these microbes might affect the cancer and treatment.
This study tests whether taking a medicine called trimethoprim, along with standard hormone therapy, can improve treatment for prostate cancer by affecting folate levels in the blood. It may help men who are about to start hormone therapy for advanced prostate cancer.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Hear when a new Prostatic Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.